In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including small cell lung cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including multiple myeloma (MM), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including breast cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read More
In a nutshell This study is searching for participants with advanced solid tumors including colorectal cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This trial is looking to trial a treatment combination of olaparib (Lynparza), durvalumab (Imfinzi), radiation therapy (RT), and chemotherapy (CT) to treat patients with extensive-stage (ES) small-cell lung cancer (SCLC). The main outcomes to be measured are side effects and survival. This trial is being carried out in Texas,...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...
Read More
In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York,...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including lung cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These tumors...
Read More
In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read More
